Conkwest Looks To Draw $173M In Latest Cancer-Focused IPO
Cancer immunotherapy treatment developer Conkwest Inc. outlined plans Friday to raise up to $172.5 million in an initial public offering, as the clinical-stage company looks to join the wave of cancer-focused...To view the full article, register now.
Already a subscriber? Click here to view full article